Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509459 | 0.89 | HTR4 (0.52) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL1502018 | 0.88 | HTR4 (0.51) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14810412 | 0.84 | HTR4 (0.59) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5042523 | 0.82 | HTR4 (0.54) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5316552 | 0.79 | HTR4 (0.47) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7333211 | 0.78 | HTR4 (0.46) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL5040326 | 0.77 | HTR4 (0.45) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL27360404 | 0.76 | HTR4 (0.50) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14810092 | 0.76 | HTR4 (0.54) | HTR4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL505954 | 0.76 | HTR4 (0.47) | HTR4HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880866-B | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-113880866-A | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-10961213-B2 | Process for preparation of benzylic amides | BASF SE (DE) | 2021-03-30 | — | — | US | disclosed |
| WO-2018137959-A1 | PROCESS FOR PREPARATION OF BENZYLIC AMIDES | BASF SE (DE) | 2018-08-02 | — | — | WO | disclosed |
| EP-0812321-B1 | PROKINETIC OXADIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-23 | — | — | EP | disclosed |
| CN-1092656-C | prokinetic oxadiazoles | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-16 | — | — | CN | disclosed |
| US-5854261-A | Prokinetic compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-29 | — | — | US | disclosed |
| CN-1177352-A | Prokinetic oxadiazoles | JANSSEN PHARMACEUTICA NV (BE) | 1998-03-25 | — | — | CN | disclosed |
| EP-0812321-A1 | PROKINETIC OXADIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-12-17 | — | — | EP | disclosed |
| WO-1996026937-A1 | PROKINETIC OXADIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961213-B2 | Process for preparation of benzylic amides | CYP2F1, BBOX1, F12 | HTR4 970/4885HTR3A 3657/4885HTR3E 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.